la Innovative Medicine Initiative ha appena lanciato la IMI2 Call 13.
I topic della call:
- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of theneurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to driveregulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects ofpharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Pilot programme on a clinical compound bank for repurposing (This programme includes the following topics: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; rare/orphan diseases)
La deadline per inviare le proposte è il 28 Febbraio 2018. Per la prima fase le proposte da preparare devono essere “short proposals”.
Il testo completo della Call e altre informazioni utili sono riportate nella pagina dedicata: http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13 .
Dal 27 novembre è iniziata la serie di webinars specifici sui vari topic della Call 13. È ancora possibile registrarsi alla maggior parte di essi visitando la pagina http://www.imi.europa.eu/news-events/events/webinars-imi2-call-13. La registrazione è gratuita, ma obbligatoria. Sono disponibili anche le registrazioni dei webinar che si sono già tenuti.
Descrizione Bando: http://www.imi.europa.eu/news-events/press-releases/cancer-neurodegenerative-disease-and-medicines-safety-feature-new-imi.